Literature DB >> 29220018

Ablynx's nanobody fragments go places antibodies cannot.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29220018     DOI： 10.1038/nbt1217-1115

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  The blinded buyer.

Authors:  Brady Huggett
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

Review 2.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

3.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

4.  Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience.

Authors:  S McGuckin; J-P Westwood; H Webster; D Collier; D Leverett; M Scully
Journal:  Vox Sang       Date:  2013-10-10       Impact factor: 2.144
  4 in total
  6 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.

Authors:  Armin Sepp; Mats Bergström; Marie Davies
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

3.  Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models.

Authors:  Cuicui Li; Jun Liu; Xu Yang; Qi Yang; Wenpeng Huang; Mingyu Zhang; Dandan Zhou; Rong Wang; Jianhua Gong; Qingfang Miao; Lei Kang; Jigang Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-05       Impact factor: 10.057

4.  The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.

Authors:  Sami El Khatib; Mohamed Salla
Journal:  Leuk Res Rep       Date:  2022-06-27

5.  Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy.

Authors:  Hao Liu; Yanli Liu; Zhen Zhao; Yuanke Li; Bahaa Mustafa; Zhijin Chen; Ashutosh Barve; Akshay Jain; Xiaolan Yao; Guangfu Li; Kun Cheng
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

Review 6.  Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.

Authors:  Ruisi Fu; Laurence Carroll; Gokhan Yahioglu; Eric O Aboagye; Philip W Miller
Journal:  ChemMedChem       Date:  2018-11-15       Impact factor: 3.466
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.